Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
Parent P, Auclin E, Patrikidou A, Mezquita L, Martínez Chanzá N, Dumont C, Rodriguez-Vida A, Llacer C, Lozano R, Ratta R, Merseburger AS, Sternberg CN, Baciarello G, Colomba E, Fuerea A, Besse B, Loriot Y, Lavaud P. Parent P, et al. Among authors: llacer c. Cancers (Basel). 2023 Feb 7;15(4):1066. doi: 10.3390/cancers15041066. Cancers (Basel). 2023. PMID: 36831409 Free PMC article.
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
Epaillard N, Parent P, Loriot Y, Lavaud P, Vera-Cea EB, Martinez-Chanza N, Rodriguez-Vida A, Dumont C, Lozano R, Llácer C, Ratta R, Oudard S, Thibault C, Auclin E. Epaillard N, et al. Among authors: llacer c. Front Oncol. 2021 May 20;11:671969. doi: 10.3389/fonc.2021.671969. eCollection 2021. Front Oncol. 2021. PMID: 34094973 Free PMC article.
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, Reid AHM, Cendón Y, Bianchini D, Llacer C, Sandhu SK, Sharp A, Rescigno P, Garcés T, Pacheco MI, Flohr P, Massard C, López-Casas PP, Castro E, de Bono JS, Olmos D. Lozano R, et al. Among authors: llacer c. Cancers (Basel). 2021 May 12;13(10):2334. doi: 10.3390/cancers13102334. Cancers (Basel). 2021. PMID: 34066080 Free PMC article.
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer.
Lorente D, Castro E, Lozano R, Puente J, Romero-Laorden N, Rodríguez-Vida A, Lainez N, Villatoro R, Llácer C, Cattrini C, Hernández A, Domenech M, Zambrana F, Almagro E, Luque R, Martinez E, López-Campos F, Gonzalez B, Méndez-Vidal MJ, Medina A, Piulats JM, Olmos D; PROREPAIR-B Study Investigators. Lorente D, et al. Among authors: llacer c. Eur Urol. 2020 Jun;77(6):763-766. doi: 10.1016/j.eururo.2020.02.025. Epub 2020 Mar 3. Eur Urol. 2020. PMID: 32143923 No abstract available.
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, Sáez MI, Herrera-Imbroda B, Montesa A, Hernández D, Villatoro R, Otero A, Correa R, Grau G, Peinado P, Pacheco MI, García-Galisteo E, Rueda A, Machuca FJ, Alba E, Márquez-Aragonés A, Olmos D, Castro E. Oliva L, et al. Among authors: llacer c. Eur Urol Oncol. 2021 Apr;4(2):315-318. doi: 10.1016/j.euo.2019.06.019. Epub 2019 Jul 13. Eur Urol Oncol. 2021. PMID: 31307957
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E. Lozano R, et al. Among authors: llacer c. Eur J Cancer. 2021 Apr;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub 2021 Feb 21. Eur J Cancer. 2021. PMID: 33626496
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Among authors: llacer c. Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11. Clin Breast Cancer. 2013. PMID: 23318089 Clinical Trial.
30 results